EYEPOINT PHARMACEUTICALS INC's ticker is EYPT and the CUSIP is 30233G209. A total of 86 filers reported holding EYEPOINT PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,178,033 | -24.7% | 4,152,445 | -18.0% | 0.02% | -19.0% |
| Q2 2023 | $44,061,869 | +159.4% | 5,064,583 | -12.3% | 0.02% | +133.3% |
| Q1 2023 | $16,987,733 | -15.9% | 5,778,140 | +0.1% | 0.01% | -18.2% |
| Q4 2022 | $20,210,782 | -54.5% | 5,774,509 | +2.9% | 0.01% | -54.2% |
| Q3 2022 | $44,374,000 | +3.5% | 5,609,877 | +2.9% | 0.02% | +14.3% |
| Q2 2022 | $42,894,000 | -33.6% | 5,450,253 | +2.5% | 0.02% | -19.2% |
| Q1 2022 | $64,636,000 | +6.7% | 5,319,828 | +7.5% | 0.03% | +18.2% |
| Q4 2021 | $60,553,000 | +83.1% | 4,947,165 | +55.8% | 0.02% | +83.3% |
| Q3 2021 | $33,076,000 | +31.6% | 3,174,337 | +13.5% | 0.01% | +20.0% |
| Q2 2021 | $25,142,000 | -14.3% | 2,796,673 | -3.2% | 0.01% | -16.7% |
| Q1 2021 | $29,345,000 | +215.4% | 2,888,247 | +104.3% | 0.01% | +200.0% |
| Q4 2020 | $9,304,000 | – | 1,413,947 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Essex Woodlands Management, Inc. | 4,190,921 | $36,461,013 | 27.59% |
| ACUTA CAPITAL PARTNERS, LLC | 382,000 | $3,323,400 | 2.25% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 3,423,897 | $29,787,904 | 1.59% |
| Cormorant Asset Management, LP | 3,200,000 | $27,840,000 | 1.56% |
| Caligan Partners LP | 310,298 | $2,699,593 | 1.52% |
| Samsara BioCapital, LLC | 432,000 | $3,758,400 | 0.66% |
| RA Capital Management | 3,370,506 | $29,323,402 | 0.55% |
| SECTORAL ASSET MANAGEMENT INC | 311,277 | $2,708,110 | 0.45% |
| ESSEX INVESTMENT MANAGEMENT CO LLC | 209,949 | $1,826,556 | 0.26% |
| BARD ASSOCIATES INC | 30,674 | $266,864 | 0.10% |